Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
- Conditions
- RSV InfectionQTc Interval
- Interventions
- Drug: zelicapavir (therapeutic dose)Drug: zelicapavir (supratherapeutic dose)Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT06601192
- Locations
- 🇺🇸
ICON Early Phase, LLC, San Antonio, Texas, United States
🇺🇸ICON, Lenexa, Kansas, United States
Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06591845
A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 69
- Registration Number
- NCT06574828
- Locations
- 🇺🇸
Austin Clinic PPD, Austin, Texas, United States
A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06462326
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 128
- Registration Number
- NCT06441318
- Locations
- 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
- Conditions
- Tuberculosis, MDRTuberculosis, PulmonaryTuberculosis, Multidrug-Resistant
- Interventions
- Drug: Control Arm FQ-S MDR/RR-TB regimen, designed according to latest WHO guidelines
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 690
- Registration Number
- NCT06441006
- Locations
- 🇲🇩
Institute of Phthisiopneumology Chiril Dragniuc, Chisinau, Moldova, Republic of
🇲🇳National Center for Communicable Diseases, Ulaanbaatar, Mongolia
🇵🇪Hospital Nacional Hipólito Unanue, Lima, Peru
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT06411860
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Limited - Leeds, Leeds, United Kingdom
A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06379867
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, China
Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.
- Conditions
- Ophthalmological Agent ToxicityBacterial Conjunctivitis
- Interventions
- Drug: VIGAMOXI®
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Target Recruit Count
- 36
- Registration Number
- NCT06363292
- Locations
- 🇲🇽
IIMET Investigación e Innovación en Medicina Traslacional, Guadalajara, Jalisco, Mexico
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 72
- Registration Number
- NCT06310876
- Locations
- 🇺🇸
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.